Status:

COMPLETED

Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

National Alliance for Research on Schizophrenia and Depression

Pfizer

Conditions:

Schizophrenia

Schizoaffective Disorder

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with ...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • To be eligible, patients must :
  • Be male or female, age 18-65
  • Be diagnosed with schizophrenia, schizoaffective disorder or bipolar disorder with psychotic features according to DSM-IV criteria
  • Be currently receiving antipsychotic drugs (clozapine, haloperidol, olanzapine, quetiapine, or risperidone) (APDs) alone, mood stabilizer(s) (MS) alone, or a combination of the two
  • Have a history of compliance with the above medication
  • Have presumptive IRS as indicated by a TG/HDL ratio \> 3.5 on current antipsychotic medication
  • Be Medicaid eligible or maintain insurance covering requested lab procedures
  • Be able to provide written informed consent Exclusion criteria
  • A patient will be considered ineligible if he/she:
  • Has a diagnosis other than schizophrenia, schizoaffective disorder or bipolar disorder with psychotic features according to DSM-IV criteria.
  • Has a history of noncompliance with prescribed psychiatric medications
  • Has a TG/HDL ratio \< 3.5 on current medication
  • Is uninsured or is unable to self-pay potential costs of required lab procedures not covered by insurance.
  • Is unable to provide written informed consent.
  • (Females only) Is pregnant, lactating or plans to become pregnant during study participation
  • Exclusion Criteria:
  • \-

Exclusion

    Key Trial Info

    Start Date :

    January 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2008

    Estimated Enrollment :

    49 Patients enrolled

    Trial Details

    Trial ID

    NCT00288366

    Start Date

    January 1 2006

    End Date

    December 1 2008

    Last Update

    August 6 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Psychiatric Hospital at Vanderbilt

    Nashville, Tennessee, United States, 37212

    Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome | DecenTrialz